Patent · US Active

GARP-TGF-β 1 IGG antibodies

US10793627B2 · kind B2 · utility

0Cited by

6References

1Claims

0Family size

Assignees

argenx BVBA · BE
UNIVERSITÉ CATHOLIQUE DE LOUVAIN · BE

Inventors

Sebastian Van Der Woning · Deinze, BE
Filip Borgions · Herk-de-Stad, BE
Torsten Dreier · Breda, NL
Lore Mariën · Evergem, BE
Gitte De Boeck · Malderen, BE
Stéphanie Liénart · Wezembeek-Oppem, BE
Sophie Lucas · Brussels, BE
Pierre Coulie · Brussels, BE

Key dates

Filing date	Nov 27, 2019
Grant date	Oct 6, 2020
Priority date	—
Expiry date	Nov 27, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-β1, particularly a complex of human GARP and human TGF-β1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-β from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.